News Headlines

  1. CRF Health Launches Self-Service Model For TrialConsent® Platform
    8/20/2018

    CRF Health, the leading global provider of patient-centered eSource technology and service solutions for the life sciences industry, launches a self-service capability and a customer enablement program to empower CROs and Sponsors to manage all aspects of electronic informed consent using a licensed, cloud-based version of the industry’s first electronic informed consent platform with fully embedded design tool.

  2. Clementia Announces Completion Of Enrollment In Phase 3 MOVE Trial For FOP
    8/16/2018

    Clementia Pharmaceuticals Inc. (NASDAQ: CMTA), a clinical-stage company innovating treatments for individuals with ultra-rare bone disorders and other diseases, today announced the early completion of patient enrollment in the MOVE Trial, Clementia’s registrational Phase 3 clinical study evaluating the safety and efficacy of palovarotene for the treatment of patients with fibrodysplasia ossificans progressiva (FOP). A total of 99 patients were enrolled in the MOVE Trial at 15 sites in 11 countries worldwide.

  3. Altasciences To Acquire Preclinical Safety Testing Services
    8/15/2018

    Altasciences announced today that it has signed a definitive agreement to acquire the preclinical testing business of SNBL U.S.A. The transaction is expected to be completed at the end of September.

  4. Inovio Announces First Patient Dosed In Trial To Determine PENNVAX®-GP’s Ability To Induce Remission Of HIV Infection
    8/14/2018

    Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that the first participant has been dosed with PENNVAX®-GP in a randomized clinical trial that will evaluate its ability to drive remission of HIV infection. 

  5. TLC Doses First Patients In Phase I/II Trial Of TLC590 For Postsurgical Pain Management
    8/14/2018

    Taiwan Liposome Company, Ltd. (4152.TWO; “TLC”), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of medical needs in pain management, ophthalmology, and oncology, today announced the dosing of the first patients in a Phase I/II trial for TLC590. To date, the trial has enrolled 12 patients, 3 of whom were dosed on August 13, 2018.

  6. Gemphire Announces Termination Of Phase 2a Clinical Trial Of Gemcabene In Pediatric NAFLD
    8/10/2018

    Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), announces today that the Data and Safety Monitoring Board (DSMB) at Emory University School of Medicine overseeing the investigator-led open label Phase 2a proof-of-concept trial evaluating gemcabene in pediatric patients with non-alcoholic fatty liver disease (NAFLD) has recommended that the trial be terminated due to unanticipated problems.

  7. Iterum Initiates SURE 1, A Phase 3 Clinical Trial Of Oral Sulopenem In Uncomplicated Urinary Tract Infections
    8/9/2018

    Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens, today announced its initiation of the first of three Phase 3 clinical trials. In this trial, known as Sulopenem for Resistant Enterobacteriaceae (SURE) 1, oral sulopenem etzadroxil combined with probenecid in a bilayer tablet (oral sulopenem) is compared to oral ciprofloxacin in women with uncomplicated urinary tract infections (uUTI). Sulopenem is Iterum’s lead compound and novel antibiotic for the treatment of gram-negative, multi-drug resistant infections

  8. Basilea Starts Clinical Phase 3 Study With Antibiotic Ceftobiprole In Staphylococcus Aureus Bacteremia (SAB)
    8/9/2018

    Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the start of a clinical phase 3 study with its antibiotic ceftobiprole. The registration study evaluates the safety and efficacy of ceftobiprole in the treatment of patients with bacteremia (bloodstream infections) caused by Staphylococcus aureus.

  9. North Americans Are The Least Informed About GDPR In Pharma, Says GlobalData
    8/9/2018

    North Americans were the least likely to say that they feel informed about the requirements of the General Data Protection Regulation (GDPR) out of those surveyed in the global pharmaceuticals industry, according to GlobalData, a leading data and analytics company.

  10. IMV Inc. Reaches Multiple Milestones In Advanced Ovarian Cancer Clinical Trial
    8/9/2018

    IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it has reached two important milestones in its ongoing clinical trial collaboration with Incyte Corporation.